Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 122 for:    stem cell arthritis AND Phase
Previous Study | Return to List | Next Study

Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04170426
Recruitment Status : Not yet recruiting
First Posted : November 20, 2019
Last Update Posted : November 22, 2019
Sponsor:
Information provided by (Responsible Party):
Celltex Therapeutics Corporation

Brief Summary:
This is an investigational new drug clinical trial for combined Phase 1 dose escalation study and Phase 2a randomized, placebo controlled and double blinded study using intravenous injection of autologous adipose stem cells (Celltex AdMSCs) for rheumatoid arthritis patients. All subjects are monitored for safety (adverse events/severe adverse events) and evaluated for RAPID3, DAS28 and ACR20 regarding AdMSCs up to 52 weeks study duration.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Biological: autologous adipose derived stem cells Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Combined Phase 1 dose escalation study and Phase 2a randomized, placebo controlled and double blinded study using autologous adipose stem cells (Celltex AdMSCs) for rheumatoid arthritis patients who failed disease-modifying antirheumatic drug (DMARDs).
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 1/2a Clinical Study for Subjects With Rheumatoid Arthritis (RA) Using Multiple Dose Intravenous Infusions of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)
Estimated Study Start Date : February 1, 2020
Estimated Primary Completion Date : December 15, 2021
Estimated Study Completion Date : December 15, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Phase 1 ARM 0
9 subjects receive dose escalation of autologous AdMSCs via Intravenous infusion in Phase 1
Biological: autologous adipose derived stem cells
Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
Other Name: Celltex-AdMSCs

Active Comparator: Phase 2 ARM 1
30 subjects receive three doses of 2.0-2.86×10^6 cells/kg on day 1, 4 and 7 via Intravenous infusion in Phase 2a
Biological: autologous adipose derived stem cells
Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
Other Name: Celltex-AdMSCs

Placebo Comparator: Phase 2 ARM 2
15 subjects receive three doses of placebo on day 1, 4 and 7 via Intravenous infusion in Phase 2a
Biological: autologous adipose derived stem cells
Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
Other Name: Celltex-AdMSCs




Primary Outcome Measures :
  1. Adverse Events and Sever Adverse Events [ Time Frame: 52 weeks ]
    The total number of adverse events and severe adverse events related and non-related with AdMSCs will be recorded to indicate the safety and tolerability.


Secondary Outcome Measures :
  1. Efficacy of Celltex AdMSCs [ Time Frame: 52 weeks ]
    Proportion of ACR 20 patients (swollen joints, tender joints, patient assessment of pain, RAPID3, DAS28-CRP and blood inflammatory panel tests) in comparison between baseline and post-treatment follow-up data.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must pass communicable disease screen tests for HIV, syphilis, Hepatitis B and C Consistent with American Rheumatism Association-European League Against Rheumatism (ACR/EULAR) 2010 rheumatoid arthritis classification criteria
  • Active Rheumatoid Arthritis, see RA functional status of class I-IV
  • Patients must meet at least one of the following: > 6 swollen joints and ≥ 6 involved joints (tenderness, swelling, deformity, pain on motion, or decreased motion) and morning stiffness ≥ 45 minutes based on 68 joint count.
  • Patients must also meet at least one of the following: rheumatoid factor (RF) > 15 IU/mL or > 1:16, C-reactive protein (CRP) > 2.0 mg/dL, Erythrocyte Sedimentation Rate (ESR) > 30 mm/hour, and anti-cyclic citrullinated protein (Anti-CCP) > 20 U/mL, TNFα > 2.8 pg/mL.
  • Patients must have failed anti-rheumatoid drug due to adverse event or inefficacy for at least 12 week and at least 4 weeks on stable dose of methotrexate ≤ 25 mg/week, or leflunomide ≤ 20 mg/day, or sulfasalazine ≤ 3 g/day, or steroids (Prednisone <10 mg/day).
  • For other medications, patients must be on the stable dose for at least 4 weeks prior to study entry in order to preclude changes to patient medication while participating on the study to ensure that a medication change could become a confounding factor in data interpretation.
  • All patients must be clinically stable with no significant changes in health status a minimum of at least 4 weeks prior to randomization and confirming patient eligibility

Exclusion Criteria:

  1. Current or prior to treatment

    • Participation in another clinical study (with use of another Investigational Medical Product) within 3 months prior to study treatment start
    • Evidence of immune suppression related to prior/current therapy
    • > 10% change in delivered monthly dose of anti-rheumatoid medications within 4 weeks prior to this stem cell infusion
    • Use of a new or additional anti-rheumatoid medication within 6 weeks prior to this stem cell infusion
    • Use of other stem cell therapy within 12 weeks prior to this stem cell therapy
    • Unwillingness or inability to comply with study procedures
  2. Concurrent Conditions

    • Clinically active malignant disease
    • Severe bladder or thrombotic disorder
    • History of known pulmonary embolism or known secondary anti-phospholipid syndrome
    • Known or suspected hypersensitivity to any components used to culture or store the AdMSCs, e.g. sulfur or sulfonamide
    • Known or suspected antibodies to any components used to culture the AdMSCs, e.g. BSA and sulfur containing products (e.g., DMSO)
    • Active infection at time of planned study treatment start
    • Age related pathology likely to inhibit study participation or completion
    • Major trauma or surgery within 14 days of study treatment start
    • Mental condition rendering the subject (or the subject's legally acceptable representative[s]) unable to understand the nature, scope and possible consequences of the study
    • Alcohol, drug, or medication abuse within one year before study treatment start
    • Any condition that, in the Investigator's opinion, is likely to interfere with evaluation of the AdMSC therapy or satisfactory conduct of the study
    • Irreversible severe end organ failure, such as heart failure/attack, stroke, liver and renal failure
    • Heavy smokers, bed-bound patients, patients or family history with hypercoagulable status, such as protein C/protein S deficiency, factor V Leiden, prothrombin gene mutation, dysfibrinogenemia, etc.
  3. Laboratory Parameters

    • Hepatic impairment, defined as any of ALT, AST, LDH or bilirubin > 2 x the upper limit of normal (ULN) range according to local laboratory standards
    • Renal impairment, defined as serum creatinine > 133 mmol/L (1.5 mg/dL)
    • Positive virology/serology for human immunodeficiency virus (HIV), hepatitis B (HBsAg positive), hepatitis C and/or syphilis
  4. Pregnancy / contraception

    • Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04170426


Contacts
Layout table for location contacts
Contact: Jane Young, MD., PhD. 7135901000 jyoung@celltexbank.com

Sponsors and Collaborators
Celltex Therapeutics Corporation
Investigators
Layout table for investigator information
Principal Investigator: Derek W Guillory, MD Root Causes Medicine

Layout table for additonal information
Responsible Party: Celltex Therapeutics Corporation
ClinicalTrials.gov Identifier: NCT04170426     History of Changes
Other Study ID Numbers: CTX0019-001
First Posted: November 20, 2019    Key Record Dates
Last Update Posted: November 22, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases